Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 2Carcinoma, Ovarian Epithelial 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Small Cell Lung Carcinoma 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1

Interventions

Gemcitabine 18Cisplatin 14Paclitaxel 9Vinblastine 7Methotrexate 7Radiotherapy 6Doxorubicin 6Carboplatin 6Fluorouracil 4Surgical Procedures, Operative 3Mitomycin 3Filgrastim 3BCG Vaccine 3Gefitinib 2Docetaxel 2Cystectomy 2valrubicin 1rubitecan 1romidepsin 1piritrexim 1merphos 1lonafarnib 1durvalumab 1avelumab 1atezolizumab 1Watchful Waiting 1Urination 1Transurethral Resection of Bladder 1Taxes 1Radiotherapy, Conformal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Urinary Bladder Neoplasms × rubitecan × Clear all
NCT00006026 2012-09-24

Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
21 enrolled
Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡